Skip to main content
×
×
Home

Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis

  • Grant E. Sara (a1), Philip M. Burgess (a2), Gin S. Malhi (a3), Harvey A. Whiteford (a4) and Wayne C. Hall (a5)...
Abstract
Background

Few studies have examined the impact of stimulant use on outcome in early psychosis. Ceasing substance use may lead to positive outcomes in psychosis.

Aims

To examine whether baseline cannabis or stimulant disorders and ongoing drug use predict readmission within 2 years of a first psychosis admission.

Method

Predictors of readmission were examined with Cox regression in 7269 people aged 15–29 years with a first psychosis admission.

Results

Baseline cannabis and stimulant disorders did not predict readmission. A stimulant disorder diagnosis prior to index psychosis admission predicted readmission, but a prior cannabis disorder diagnosis did not. Ongoing problem drug use predicted readmission. The lowest rate of readmission occurred in people whose baseline drug problems were discontinued.

Conclusions

Prior admissions with stimulant disorder may be a negative prognostic sign in first-episode psychosis. Drug use diagnoses at baseline may be a good prognostic sign if they are identified and controlled.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis
      Available formats
      ×
Copyright
Corresponding author
Dr Grant Sara, Director, InforMH, Macquarie Hospital, PO Box 169, North Ryde, NSW 1670, Australia. Email: Grant.Sara@health.nsw.gov.au
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Álvarez-Jiménez, M, Parker, AG, Hetrick, SE, McGorry, PD, Gleeson, JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 2011; 37: 619–30.
2 Gonzalez-Pinto, A, Alberich, S, Barbeito, S, Gutierrez, M, Vega, P, Ibanez, B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011; 37: 631–9.
3 Bertelsen, M, Jeppesen, P, Petersen, L, Thorup, A, Ohlenschlaeger, J, Le Quach, P, et al. Course of illness in a sample of 265 patients with first-episode psychosis – five-year follow-up of the Danish OPUS trial. Schizophr Res 2009; 107: 173–8.
4 Wade, D, Harrigan, S, Edwards, J, Burgess, PM, Whelan, G, McGorry, PD. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 2006; 81: 145–50.
5 Sara, G, Burgess, P, Malhi, G, Whiteford, H, Hall, W. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res 2013; 147: 216–22.
6 Hides, L, Dawe, S, Kavanagh, DJ, Young, RM. Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. Br J Psychiatry 2006; 189: 137–43.
7 Degenhardt, L, Dierker, L, Chiu, WT, Medina-Mora, ME, Neumark, Y, Sampson, N, et al. Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend 2010; 108: 8497.
8 Kittirattanapaiboon, P, Mahatnirunkul, S, Booncharoen, H, Thummawomg, P, Dumrongchai, U, Chutha, W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev 2010; 29: 456–61.
9 Gleeson, JFM, Alvarez-Jimenez, M, Cotton, SM, Parker, AG, Hetrick, S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 2010; 119: 7988.
10 Centre for Epidemiology and Evidence. Health Statistics New South Wales: NSW Population. NSW Ministry of Health, 2012.
11 Yung, AR, McGorry, PD. Prediction of psychosis: setting the stage. Br J Psychiatry 2007; 191 (suppl 51): s18.
12 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. WHO, 1992.
13 Wing, JK, Beevor, AS, Curtis, RH, Park, SB, Hadden, S, Burns, A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry 1998; 172: 11–8.
14 Burgess, P, Trauer, T, Coombs, T, McKay, R, Pirkis, J. What does ‘clinical significance’ mean in the context of the Health of the Nation Outcome Scales? Australas Psychiatry 2009; 17: 141–8.
15 Malla, A, Norman, R, Bechard-Evans, L, Schmitz, N, Manchanda, R, Cassidy, C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med 2008; 38: 1585–93.
16 Addington, DE, Beck, C, Wang, J, Adams, B, Pryce, C, Zhu, H, et al. Predictors of admission in first-episode psychosis: developing a risk adjustment model for service comparisons. Psychiatr Serv 2010; 61: 483–8.
17 González-Pinto, A, Alberich, S, Barbeito, S, Gutierrez, M, Vega, P, Ibáñez, B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011; 37: 631–9.
18 Addington, J, Addington, D. Effect of substance misuse in early psychosis. Br J Psychiatry 1998; 172 (suppl 33): 134–6.
19 Degenhardt, L, Roxburgh, A, McKetin, R. Hospital separations for cannabis-and methamphetamine-related psychotic episodes in Australia. Med J Aust 2007; 186: 342–5.
20 Curran, C, Byrappa, N, Mcbride, A. Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185: 196204.
21 Hermens, DF, Lubman, DI, Ward, PB, Naismith, SL, Hickie, IB. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 2009; 190 (suppl 4): s225.
22 Strakowski, SM, DelBello, MP, Fleck, DE, Adler, CM, Anthenelli, RM, Keck, PE Jr, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007; 64: 5764.
23 Baeza, I, Graell, M, Moreno, D, Castro-Fornieles, J, Parellada, M, Gonzalez-Pinto, A, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res 2009; 113: 129–37.
24 Lambert, M, Conus, P, Lubman, DI, Wade, D, Yuen, H, Moritz, S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141–8.
25 Gupta, P, Mullin, K, Nielssen, O, Harris, A, Large, M. Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. Aust NZ J Psychiatry 2013; 47: 524–37.
26 Rabin, RA, Zakzanis, KK, George, TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res 2011; 128: 111–6.
27 Yucel, M, Bora, E, Lubman, DI, Solowij, N, Brewer, WJ, Cotton, SM, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012; 38: 316–30.
28 Mueser, KT, Drake, RE, Wallach, MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998; 23: 717–34.
29 Schnell, T, Koethe, D, Daumann, J, Gouzoulis-Mayfrank, E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berlin) 2009; 205: 4552.
30 Loberg, EM, Hugdahl, K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci 2009; 3: 53.
31 Mathias, S, Lubman, DI, Hides, L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008; 69: 358–67.
32 Crebbin, K, Mitford, E, Paxton, R, Turkington, D. First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 710–5.
33 Arendt, M, Rosenberg, R, Foldager, L, Perto, G, Munk-J⊘rgensen, P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005; 187: 510–5.
34 Durbin, J, Lin, E, Layne, C, Teed, M. Is readmission a valid indicator of the quality of inpatient psychiatric care? J Behav Health Serv Res 2007; 34: 137–50.
35 Sipos, A, Harrison, G, Gunnell, D, Amin, S, Singh, SP. Patterns and predictors of hospitalisation in first-episode psychosis. Prospective cohort study. Br J Psychiatry 2001; 178: 518–23.
36 Petersen, L, Jeppesen, P, Thorup, A, Abel, M-B, Øhlenschlæger, J, Christensen, , et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005; 331: 602–5.
37 Wade, D, Harrigan, S, Harris, MG, Edwards, J, McGorry, PD. Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis. Aust NZ J Psychiatry 2006; 40: 429–36.
38 Compton, MT, Gordon, TL, Goulding, SM, Esterberg, ML, Carter, T, Leiner, AS, et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. J Clin Psychiatry 2011; 72: 225–32.
39 Warner, R. Recovery from schizophrenia and the recovery model. Curr Opin Psychiatry 2009; 22: 374–80.
40 Emsley, R, Chiliza, B, Asmal, L, Lehloenya, K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry 2011; 24: 114–21.
41 Stowkowy, J, Addington, D, Liu, L, Hollowell, B, Addington, J. Predictors of disengagement from treatment in an early psychosis program. Schizophr Res 2012; 136: 712.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 23 *
Loading metrics...

Abstract views

Total abstract views: 87 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 25th April 2018. This data will be updated every 24 hours.

Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis

  • Grant E. Sara (a1), Philip M. Burgess (a2), Gin S. Malhi (a3), Harvey A. Whiteford (a4) and Wayne C. Hall (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *